46 results on '"Price, Karen"'
Search Results
2. Gait Changes Following Myofascial Structural Integration (Rolfing) Observed in 2 Children With Cerebral Palsy
3. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
4. Myofascial Structural Integration: A Promising Complementary Therapy for Young Children With Spastic Cerebral Palsy
5. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
6. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
7. Survey results on the use of the tissue cross-reactivity immunohistochemistry assay
8. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
9. Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
10. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy
11. Simultaneous Changes In Muscle Carnosine and Taurine During and Following Supplementation with b-alanine: 928: June 4 2:15 PM - 2:30 PM
12. Referrals into services for offenders with intellectual disabilities: Variables predicting community or secure provision
13. REASONS FOR AND AGAINST ILLICIT DRUG USE AMONG ELITE AUSTRALIAN ATHLETES: Paper No 34
14. ILLICIT DRUG EDUCATION AND ELITE AUSTRALIAN ATHLETES: WHAT DO THEY KNOW, WHAT DO THEY WANT TO KNOW, AND HOW CAN WE TELL THEM?: Paper No 35
15. THE PERCEPTIONS OF ATHLETE AND SUPPORT STAFF REGARDING POLICIES THAT REGULATE DRUG USE IN SPORT: Paper No 37
16. THE PREVALENCE AND PATTERNS OF ILLICIT DRUG USE AMONG ELITE AUSTRALIAN ATHLETES: Paper No 36
17. Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century
18. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93
19. Unraveling the Genetic Landscape of Bladder Development in Mice
20. Selective PKC Beta Inhibition with Ruboxistaurin and Endothelial Function in Type-2 Diabetes Mellitus
21. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
22. Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
23. Correlation of vibratory quantitative sensory testing and nerve conduction studies in patients with diabetes
24. Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials
25. The phagocytic capacity of neurones
26. Comparing Aromatase Inhibitors in the Absence of Clinical Trial Results Can Be Misleading
27. Big brown dog or brown big dog? An electrophysiological study of semantic constraints on prenominal adjective order
28. Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays
29. Human Vascular Smooth Muscle Cells Express a Urate Transporter
30. SURAL SENSORY ACTION POTENTIAL IDENTIFIES DIABETIC PERIPHERAL NEUROPATHY RESPONDERS TO THERAPY
31. Loss of nitric oxide and endothelial-derived hyperpolarizing factor–mediated responses in aging
32. Prognostic Value of Extracapsular Tumor Spread for Locoregional Control in Premenopausal Patients With Node-Positive Breast Cancer Treated With Classical Cyclophosphamide, Methotrexate, and Fluorouracil: Long-Term Observations From International Breast Cancer Study Group Trial VI
33. Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience
34. Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
35. Evolving Concepts in Human Renal Dysplasia
36. Adjuvant Endocrine Therapy Compared With No Systemic Therapy for Elderly Women With Early Breast Cancer: 21-Year Results of International Breast Cancer Study Group Trial IV
37. Communities of aquatic insects of old-growth and clearcut coastal headwater streams of varying flow persistence
38. OFD1, the Gene Mutated in Oral-Facial-Digital Syndrome Type 1, Is Expressed in the Metanephros and in Human Embryonic Renal Mesenchymal Cells
39. Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer
40. Identifying Breast Cancer Patients at High Risk for Bone Metastases
41. Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII
42. Early Start of Adjuvant Chemotherapy May Improve Treatment Outcome for Premenopausal Breast Cancer Patients With Tumors not Expressing Estrogen Receptors
43. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil
44. Mineral Dusts Directly Induce Epithelial and Interstitial Fibrogenic Mediators and Matrix Components in the Airway Wall
45. University-based sports pharmacy program
46. Effect of systemic adjuvant treatment on first sites of breast cancer relapse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.